Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Osteosarcoma
is one of the most common primary malignant bone tumors in adolescents. It is associated with high risk of relapse and the outcomes of patients with high-grade
osteosarcoma
remain poor. Therefore, additional studies investigating the molecular mechanisms involved in tumor initiation, growth, migration and invasion of
osteosarcoma
are necessary. In the present study, the protein levels of solute carrier family 25 member 10 (
SLC25A10
) were increased in
osteosarcoma
tissue, compared with normal bone tissue. In patients with
osteosarcoma
, high expression levels of
SLC25A10
were associated with poor clinicopathological parameters, including metastasis, clinical Enneking stage, relapse-free survival and overall survival rates. Short hairpin RNA knockdown of
SLC25A10
significantly suppressed cell proliferation as determined by cell counting, MTT assay and cell colony formation assays. In addition,
SLC25A10
knockdown caused an increase in apoptosis and a decrease in mitosis in
osteosarcoma
cells. Cyclin E1 (CCNE1) was positively regulated by
SLC25A10
, while P21 and P27 were negatively regulated by
SLC25A10
. Therefore,
SLC25A10
may play an oncogenic role in human
osteosarcoma
, which could be mediated by CCNE1, P21 and P27.
...
PMID:SLC25A10 performs an oncogenic role in human osteosarcoma. 3277 76